Abstract:Ara h 2 structure determined in complex with human antibodies. Hypoallergen engineered for reduced IgE binding. Hypoallergen demonstrates reduced anaphylaxis in mice primed with peanut allergic serum. Introduction Adverse reactions are relatively common during peanut oral immunotherapy. To reduce the risk to the patient, some researchers have proposed modifying the allergen to reduce IgE reactivity, creating a putative hypoallergen. Analysis of recently cloned human IgG from patients treated with peanut immunotherapy suggested that there are three common conformational epitopes for the major peanut allergen Ara h 2. We sought to test if structural information on these epitopes could indicate mutagenesis targets for designing a hypoallergen and evaluated the reduction in IgE binding via immunochemistry and a mouse model of passive cutaneous anaphylaxis (PCA). Methods X‐ray crystallography characterized the conformational epitopes in detail, followed by mutational analysis of key residues to modify monoclonal antibody (mAb) and serum IgE binding, assessed by ELISA and biolayer interferometry. A designed Ara h 2 hypoallergen was tested for reduced vascularization in mouse PCA experiments using pooled peanut allergic patient serum. Results A ternary crystal structure of Ara h 2 in complex with patient antibodies 13T1 and 13T5 was determined. Site‐specific mutants were designed that reduced 13T1, 13T5, and 22S1 mAbs binding by orders of magnitude. By combining designed mutations from the three major conformational bins, a hexamutant (Ara h 2 E46R, E89R, E97R, E114R, Q146A, R147E) was created that reduced IgE binding in serum from allergic patients. Further, in the PCA model where mice were primed with peanut allergic patient serum, reactivity upon allergen challenge was significantly decreased using the hexamutant. Conclusion These studies demonstrate that prior knowledge of common conformational epitopes can be used to engineer reduced IgE reactivity, an important first step in hypoallergen design.

Full-Wave Analysis and Applications of EBG Waveguides Periodically Loaded with Metal Ridges

Generation of IgE-specific Cytotoxic T Lymphocytes As a Novel Immunotherapeutic Approach for the Treatment of Allergic Asthma.

The Potential of Human Monoclonal IgE Antibodies to Establish Biological Potency and Stability of Allergen Extracts

A therapeutic strategy to target distinct sources of IgE and durably reverse allergy

Rapid platelet inhibition after a single capsule of Aggrenox®: Challenging a conventional full‐dose aspirin antiplatelet advantage?

A Novel Method for Total IgE Purification from Human Serum

Design of an Ara h 2 hypoallergen from conformational epitopes

Feasibility of plant-expression system for production of recombinant anti-human IgE: An alternative production platform for therapeutic monoclonal antibodies

Microfluidic system for high-throughput immunoglobulin-E analysis from clinical serum samples

Is Human IgE+ Equivalent to Mouse Highly Cytokinergic (HC) IgE?

Detection of specific immunoglobulin E antibodies toward common airborne allergens, peanut, wheat, and latex in solvent/detergent-treated pooled plasma

Novel IgE crosslinking-induced luciferase expression method using human-rat chimeric IgE receptor-carrying mast cells

Precision engineering for localization, validation and modification of allergenic epitopes

A Comparison of Natural and Therapeutic Anti-IgE Antibodies

Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies

IgE binding epitope mapping with TL1A tagged peptides

[Contribution of fiberendoscopy to the treatment of nonneoplastic esophageal stenosis].

A Cell-Free Protein Synthesis Platform to Produce a Clinically Relevant Allergen Panel

Development of an epitope-specific analytical tool for the major peanut allergen Ara h 2 using a high-density multiple-antigenic peptide strategy

Anti-Peptide Antibody Production Elicited by in Vitro Immunization of Human Peripheral Blood Mononuclear Cells

Platelet-compatible hydrophilic segmented polyurethanes from polyethylene glycols and cyclohexane diisocyanate.